Weekly News – October 20
The next shoe to drop:
The Complex Case Panel under scrutiny
Reorg’s Court Opinion Review opinions are not necessarily those of Reorg as a whole.
We want to hear from you
Should we dust off our letter from 2022?
and even more fall-out…
Rite Aid files for BK in New Jersey
Forum shopping part deux?
Liability Management 101
This highly sourced research shows a 23% recovery differential for primed lenders & also provides some hope that the pendulum is swinging back to the use of coop agreements.
Let us know what you think
FTX clears hurdle
Purdue briefing complete
Tons of Macro
10-yr Yield hits 5%
With no relief in sight…
and China isn’t helping
Coming up this week!
This event is available to institutional investors only
Featured Event: Beard Investing Conference
CRC weighs in on Serta
The Academics Speak Up
Purdue Pharma is the gift that keeps on giving. This is our third installment on the twists and turns this case has taken through the Courts. You can read our first installment here, and our second here.
All bets came off the table when the Supreme Court decided to reshuffle the deck by taking on the appeal of the 2nd Circuit’s decision. Not only did SCOTUS take the unusual step of taking on this big ticket issue in BK cases but it also stopped the lower court’s decision in its tracks putting the breaks on the entire enchilada. We decided to consult with our expert Academic Contributors for our inaugural feature the Academics Speak Up to get their takes on the latest developments.
We are excited to bring you the varying perspectives of Prof. Tony Casey, Prof. Samir Parikh and Prof. Ralph Brubaker.
Read more on Purdue Pharma
click through to read the features from our Contributors
Read our recent coverage:
Where Are We In The Credit Cycle?
Look out for more great features from our Contributors
Have something interesting to share?
email us at [email protected]